These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27168275)

  • 1. Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque Psoriasis.
    Rothstein BE; McQuade B; Greb JE; Goldminz AM; Gottlieb AB
    J Drugs Dermatol; 2016 May; 15(5):648-9. PubMed ID: 27168275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis.
    Sacchelli L; Patrizi A; Loi C; Bardazzi F
    Clin Exp Dermatol; 2019 Oct; 44(7):e243-e244. PubMed ID: 31055844
    [No Abstract]   [Full Text] [Related]  

  • 3. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
    Danesh MJ; Beroukhim K; Nguyen C; Levin E; Koo J
    Dermatol Online J; 2015 Jun; 21(6):. PubMed ID: 26158370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
    Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
    Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
    J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One stone, two birds: Improvement of early-onset vitiligo under apremilast in a patient with plaque psoriasis.
    Plachouri KM; Kyriakou G; Chourdakis V; Georgiou S; Grafanaki K
    Dermatol Ther; 2019 Sep; 32(5):e13064. PubMed ID: 31414705
    [No Abstract]   [Full Text] [Related]  

  • 10. Real-World Experience With Apremilast in Treating Psoriasis.
    Mayba JN; Gooderham MJ
    J Cutan Med Surg; 2017; 21(2):145-151. PubMed ID: 27846617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Lichen Planus Treated With Apremilast.
    Bettencourt M
    J Drugs Dermatol; 2016 Aug; 15(8):1026-8. PubMed ID: 27538007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy.
    Aljaser M; Amar L; Kircik LH
    J Drugs Dermatol; 2019 Apr; 18(4):336-340. PubMed ID: 31012561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
    Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
    J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.
    Krishnamoorthy G; Kotecha A; Pimentel J
    BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30709830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective treatment of nail psoriasis with apremilast: report of two cases and review of the literature.
    Magdaleno-Tapial J; Valenzuela-Oñate C; Ortiz-Salvador JM; Subiabre-Ferrer D; Hernández-Bel P
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
    J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
    Radi G; Campanati A; Diotallevi F; Molinelli E; Offidani A
    G Ital Dermatol Venereol; 2019 Apr; 154(2):166-169. PubMed ID: 30229640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
    Nast A; Spuls PI; van der Kraaij G; Gisondi P; Paul C; Ormerod AD; Saiag P; Smith CH; Dauden E; de Jong EM; Feist E; Jobling R; Maccarone M; Mrowietz U; Papp KA; Reich K; Rosumeck S; Talme T; Thio HB; van de Kerkhof P; Werner RN; Dressler C
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1951-1963. PubMed ID: 28895202
    [No Abstract]   [Full Text] [Related]  

  • 20. ▼ Apremilast for psoriasis and psoriatic arthritis.
    Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.